Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¶ó¹ÌºÎµò Ä¡·á ÁßÀÎ ¸¸¼º BÇü °£¿° ¹ÙÀÌ·¯½º °¨¿° ȯÀÚ¿¡¼­ BÇü °£¿° ¹ÙÀÌ·¯½º ¿ªÀü»çÈ¿¼ÒÀÇ º¯ÀÌ ¾ç»ó Pattern of Mutations in Hepatitis B Virus Reverse Transcriptase Gene during Lamivudine Therapy in Patients with Chronic Hepatitis B Virus Infection

´ëÇѼÒÈ­±âÇÐȸÁö 2003³â 41±Ç 6È£ p.480 ~ 485
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌ»ó¿ë/Lee SY ÇãÁ¤/ÃÖö¿õ/ÀÌÁÖÈ£/±è±¤ÇÏ/°­´ëȯ/¼Û±Ù¾Ï/Á¶¸ù/¾ç¿õ¼®/ÀåÇöÁ¤/¹ÚÈñ°æ/Heo J/Choi CW/Lee JH/Kim GH/Kang DH/Song GA/Cho M/Yang US/Jang HJ/Park HK

Abstract

Background/Aims: Lamivudine resistant hepatitis B viruses (HBV) by mutations of YMDD motif in the HBV reverse transcirptase are very common in the patients with long-term lamivudine therapy. We investigated the pattern of mutations in and outside of YMDD motif of HBV reverse transcriptase gene during lamivudine therapy in patients with chronic hepatitis B infection. Methods: The study included 80 patients with chronic hepatitis B infection. To determine mutations in the HBV reverse transcriptase, the nucleotide 581-870 of the HBV reverse transcriptase was amplified and analyzed by direct sequencing method. Results: Amino acid changes were detected in 45 (56%) out of 80 patients. YMDD mutants were detected in 62% (28/45) and amino acid changes were detected outside of YMDD motif in 38% (17/45). M552I (82%, 23/28) was more common than M552V (18%, 5/28) in YMDD mutants. L528M was noted in 27% (12/45). F569Y (13%, 6/45), S571A (13%, 6/45), I572V (18%, 8/45) were common amino acid changes. Conclusions: Mutations were frequently detected outside of YMDD motif as well as YMDD motif of HBV reverse transcriptase gene in patients with lamivudine therapy. Most of the mutations in outside of YMDD motif were combined with YMDD mutants. No consistent mutation was found outside of YMDD motif in lamivudine resistant patients.


¸ñÀû: HBV DNA ¿ªÀü»çÈ¿¼Ò YMDD ¿µ¿ªÀÇ M552I¿Í M552V µ¹¿¬º¯ÀÌ´Â ¶ó¹ÌºÎµò¿¡ ÀúÇ×¼ºÀ» °¡Áö´Â °ÍÀ¸·Î Àß ¾Ë·ÁÁ® ÀÖÀ¸³ª YMDD ÀÌ¿ÜÀÇ HBV DNA ¿ªÀü»çÈ¿¼Ò¿µ¿ªÀÇ º¯ÀÌÀÇ Á¸Àç¿Í Àǹ̿¡ ´ëÇؼ­´Â ¾ÆÁ÷ Àß ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù. ÀÌ¿¡ ÀúÀÚ´Â ¶ó¹ÌºÎµòÀ¸·Î Ä¡·á ÁßÀÎ ¸¸¼º BÇü °£Áúȯ ȯÀÚ¿¡¼­ HBV DNA ¿ªÀü»çÈ¿¼Ò ¿µ¿ª Áß YMDD ¿µ¿ª°ú ±× ÁÖÀ§ ¿µ¿ªÀÇ º¯ÀÌÀÇ ºÐÆ÷¸¦ ¾Ë¾Æº¸°í, YMDD ¿µ¿ª ÀÌ¿ÜÀÇ º¯ÀÌ¿Í ÀÓ»óÀû ³»¼º°úÀÇ °ü·Ã¼ºÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù. ´ë»ó ¹× ¹æ¹ý: ¶ó¹ÌºÎµòÀ¸·Î Ä¡·á¸¦ ¹Þ°í ÀÖ´Â ¸¸¼º BÇü °£Áúȯ ȯÀÚ 80¸íÀ» ¹«ÀÛÀ§·Î ¼±ÅÃÇÏ¿© HBV DNA Á¤·®À» ÇÏ¿´°í, nested PCR ¹æ¹ýÀ» ÀÌ¿ëÇÏ¿© HBV DNA ¿ªÀü»çÈ¿¼Ò ¿µ¿ªÀ» Á÷Á¢ ¿°±â¼­¿­ ºÐ¼®ÇÏ¿´´Ù. °á°ú: Àüü 80¿¹ Áß 45¿¹(56%)¿¡¼­ ¾Æ¹Ì³ë»êÀÇ º¯ÀÌ°¡ °üÂûµÇ¾ú°í, 14¿¹¿¡¼­ ¾ß»ýÇüÀÌ °üÂûµÇ¾úÀ¸¸ç, 21¿¹´Â nested PCR¿¡¼­ HBV DNA°¡ °ËÃâµÇÁö ¾Ê¾Ò´Ù. Àüü ¾Æ¹Ì³ë»êÀÇ º¯ÀÌ°¡ ÀÖ¾ú´ø 45¿¹ Áß 28¿¹(62%)¿¡¼­ YMDD ¿µ¿ªÀÇ 552¹ø ¾Æ¹Ì³ë»ê(M) µ¹¿¬º¯ÀÌ°¡ ¹ß»ýÇÏ¿´´Ù. 28¿¹ Áß 23¿¹´Â M552I, 5¿¹°¡ M552V¿´´Ù. M552V µ¹¿¬º¯ÀÌ´Â Ç×»ó L528M º¯À̸¦ µ¿¹ÝÇÏ¿´´Ù. YMDD ÀÌ¿ÜÀÇ ¿µ¿ª¿¡¼­´Â L528M, F569Y, S571A, I572VÀÇ ¾Æ¹Ì³ë»êÀÇ º¯ÀÌ°¡ ¸¹¾Ò´Ù. ÀÓ»óÀû ³»¼ºÀ» º¸ÀÎ 22¿¹ Áß ¾Æ¹Ì³ë»ê º¯À̸¦ µ¿¹ÝÇÑ ¿¹´Â 14¿¹(64%)¿´°í, ÀÌ Áß 10¿¹°¡ YMDD µ¹¿¬º¯ÀÌ¿´°í, 4¿¹´Â YMDD ¿µ¿ª°ú ¹«°üÇÑ µ¹¿¬º¯ÀÌ¿´´Ù. ³ª¸ÓÁö 8¿¹´Â ¾î¶² ¾Æ¹Ì³ë»ê º¯È­µµ °üÂûµÇÁö ¾Ê¾Ò´Ù. °á·Ð: ¶ó¹ÌºÎµòÀ¸·Î Ä¡·á¹Þ°í ÀÖ´Â ¸¸¼º BÇü °£Áúȯ ȯÀÚ¿¡¼­ YMDD ¿µ¿ªÀÇ º¯ÀÌ´Â ÈçÇϸç ÁÖ·Î M552IÇüÀ̾ú´Ù. YMDD ÀÌ¿ÜÀÇ ¿µ¿ª¿¡¼­ÀÇ ¾Æ¹Ì³ë»êÀÇ º¯À̵µ ºó¹øÇÏ¿´´Ù. YMDD ¿µ¿ªÀÇ º¯ÀÌ¿Í ¹«°üÇÑ YMDD ÀÌ¿ÜÀÇ ¿ªÀü»çÈ¿¼ÒÀÇ ¾Æ¹Ì³ë»ê º¯È­¸¦ ¾ß±âÇÏ´Â º¯ÀÌ´Â ÀÏÁ¤ÇÑ ¾ç»óÀ» º¸ÀÌÁö ¾Ê¾ÒÀ¸¸ç ÀÓ»óÀûÀÎ ¶ó¹ÌºÎµò ³»¼º°úÀÇ °ü·Ã¼º¿¡ ´ëÇؼ­´Â ¿¬±¸°¡ ´õ ÇÊ¿äÇÏ´Ù.

Å°¿öµå

YMDD mutations; Lamivudine; Hepatitis B virus; YMDD µ¹¿¬º¯ÀÌ; ¶ó¹ÌºÎµò; BÇü °£¿° ¹ÙÀÌ·¯½º

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS